Pax3 Stimulates p53 Ubiquitination and Degradation Independent of Transcription by Wang, Xiao Dan et al.
Pax3 Stimulates p53 Ubiquitination and Degradation
Independent of Transcription
Xiao Dan Wang, Sarah C. Morgan, Mary R. Loeken*
Section on Developmental and Stem Cell Biology, Department of Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States of
America
Abstract
Background: Pax3 is a developmental transcription factor that is required for neural tube and neural crest development. We
previously showed that inactivating the p53 tumor suppressor protein prevents neural tube and cardiac neural crest defects
in Pax3-mutant mouse embryos. This demonstrates that Pax3 regulates these processes by blocking p53 function. Here we
investigated the mechanism by which Pax3 blocks p53 function.
Methodology/Principal Findings: We employed murine embryonic stem cell (ESC)-derived neuronal precursors as a cell
culture model of embryonic neuroepithelium or neural crest. Pax3 reduced p53 protein stability, but had no effect on p53
mRNA levels or the rate of p53 synthesis. Full length Pax3 as well as fragments that contained either the DNA-binding
paired box or the homeodomain, expressed as GST or FLAG fusion proteins, physically associated with p53 and Mdm2 both
in vitro and in vivo. In contrast, Splotch Pax3, which causes neural tube and neural crest defects in homozygous embryos,
bound weakly, or not at all, to p53 or Mdm2. The paired domain and homeodomain each stimulated Mdm2-mediated
ubiquitination of p53 and p53 degradation in the absence of the Pax3 transcription regulatory domains, whereas Splotch
Pax3 did not stimulate p53 ubiquitination or degradation.
Conclusions/Significance: Pax3 inactivates p53 function by stimulating its ubiquitination and degradation. This process
utilizes the Pax3 paired domain and homeodomain but is independent of DNA-binding and transcription regulation.
Because inactivating p53 is the only required Pax3 function during neural tube closure and cardiac neural crest
development, and inactivating p53 does not require Pax3-dependent transcription regulation, this indicates that Pax3 is not
required to function as a transcription factor during neural tube closure and cardiac neural crest development. These
findings further suggest novel explanations for PAX3 functions in human diseases, such as in neural crest-derived cancers
and Waardenburg syndrome types 1 and 3.
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Introduction
Understanding how regulators of embryonic development
function on a molecular level is a major objective of developmental
biology. Pax3, a member of the mammalian Pax family of
developmental regulators, is expressed in the neuroepithelium,
neural crest, and somitic mesoderm [1,2,3]. One hundred percent
of mouse embryos that are homozygous for the mutant Pax3 allele,
Splotch (Pax3
Sp/Sp) develop neural tube defects (NTD), cardiac
outflow tract defects (COTD), and fail to form skeletal muscle,
indicating that Pax3 is essential for formation of these structures
[4,5,6]. In humans, Waardenburg syndrome (WS) types 1 and 3 is
an autosomal dominant condition that is caused by PAX3
mutations and affects neural crest-derived structures, [7]. Pax
proteins are characterized by the presence of a paired box DNA-
binding element [1]. Some of the Pax proteins, including Pax3,
contain a paired-type homeodomain that also binds to DNA, and
a conserved octapeptide [1]. It has traditionally been accepted that
Pax3 regulates developmental processes by operating as a
transcriptional regulator because: (i) Pax3 contains sequence-
specific DNA-binding domains that are capable of directing trans-
activation [8,9,10]; (ii) the protein product of the mutant Splotch
Pax3 allele is trans-activation defective [11]; and (iii) several genes
have been identified that are directly or indirectly regulated by
Pax3 [12,13,14,15,16,17,18,19,20,21,22,23]. However, exactly
how Pax3 regulates formation of the neural tube and neural
crest-dependent structures has not yet been determined.
Apoptotic cells are observed in embryos expressing nonfunc-
tional Pax3 alleles at sites where normal Pax3-expressing
neuroepithelial and cardiac neural crest cells are located in w.t.
embryos [24,25,26]. This suggests that the ensuing NTD and
COTD result from depletion of progenitor cells that are necessary
to populate these structures. We showed that inactivation of p53
through germ-line mutation or chemical inhibition prevented the
NTD, exencephaly and spina bifida, and COTD that are
characteristic of Pax3
Sp/Sp embryos, as well as associated apoptosis,
in embryos expressing nonfunctional Pax3 alleles [25,27]. This
indicates that Pax3 is not required in neuroepithelium and neural
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that it is required to block p53-dependent processes that lead to
apoptosis. This contrasts with the role of Pax3 in skeletal muscle
development where it serves as an upstream regulator of myogenic
gene expression [16,17]. p53 protein, but not mRNA, was
increased in Pax3
Sp/Sp embryos, suggesting that Pax3 blocks p53
function by inhibiting p53 protein synthesis, stability, or both [27].
However, the precise mechanism by which Pax3 regulates steady
state levels of p53 protein, and whether it involved Pax3
functioning as a transcription factor, has not been determined.
Further study of the molecular mechanism by which Pax3
regulates p53 can be facilitated by a cell culture model of
developing neuroepithelium and neural crest. Murine embryonic
stem cells (ESC) can be induced to form neuronal precursors that
express genes that are characteristic of neuroepithelium, including
Pax3 [28]. Thus, if expression of Pax3 causes a reduction in steady-
state levels of p53 protein, differentiating ESC would be a valid cell
culture model to study the mechanism by which Pax3 blocks p53
function in embryonic neuroepithelium and neural crest.
Results
p53 protein is negatively regulated by Pax3 in ESC
We first investigated whether abundance of p53 protein, but not
mRNA, was inversely related to abundance of Pax3 in ESC as in
mouse embryos. Murine ESC were grown as undifferentiated
cultures (stage 1), or were induced to form neuroepithelial-like
neuronal precursors (stage 3) using established methods [29].
There was no difference in abundance of p53 mRNA between
stage 1 and stage 3 (Figure 1 A). In contrast, Pax3 mRNA was
undetectable in stage 1 ESC but was significantly increased during
stage 3. Nestin mRNA, which is expressed in neuroepithelium in
vivo and in mESC-derived neuronal precursors [29,30] increased
in stage 3 ESC. In contrast to p53 mRNA, p53 protein
significantly decreased during ESC differentiation, while Pax3
protein increased in parallel to Pax3 mRNA (Figure 1 B). Nestin
protein levels also significantly increased in stage 3 ESC.
Immunofluorescence using antibodies against p53 or Pax3 further
supported that p53 and Pax3 protein abundance are inversely
related in undifferentiated and differentiating ESC (Figure 1 C, D).
Thus, in ESC, just as in mouse embryos, p53 protein, but not
mRNA, is inversely related to production of Pax3.
To test whether Pax3 was responsible for the decrease in p53
protein in differentiating ESC the effects of expressing Pax3 in
stage 1 ESC, and of knocking down expression of Pax3 in stage 3
ESC, on p53 were examined. Transfecting ESC with a Pax3
expression vector showed that constitutive expression of Pax3 had
no effect on p53 mRNA (Figure 1 E) but was sufficient to suppress
p53 protein in stage 1 ESC (Figure 1 F). Conversely, knocking
down Pax3 using an inducible shRNA in stage 3 ESC increased
Figure 1. Pax3 negatively regulates p53 protein, but not mRNA levels in ESC just as in mouse embryos. (A) Real time RT-PCR of p53,
Pax3, and Nestin mRNA in stage 1 (open bars) and stage 3, days 2–8 (solid bars) ESC. Nestin mRNA is expressed in neuroepithelium and in ESC-derived
neuronal precursors [29,30] and served as a control for a marker of neuroepithelial neuronal precursors. Each mRNA was normalized to rRNA. In (A),
(B), and (D) values represent the mean 6 SEM (n=3 culture dishes). *p,0.01 vs. stage 1. (B) Quantification (band intensity in arbitrary units) of
immunoblots of p53, Pax3, and Nestin normalized to b-actin in stage 1 and stage 3 ESC harvested on days as indicated in (A). (C) Indirect
immunofluorescence of p53 (green) and Pax3 (red) in stage 1 and stage 3 ESC. Cells were counterstained with DAPI (blue) to visualize nuclei. Cells
incubated with secondary antibodies alone generated no detectable signals (not shown). (D) Percent Pax3 or p53 positive cells in stage 1 and stage 3
ESC. Values represent the mean 6 SEM (n=10 fields). (E) Real time RT-PCR of Pax3 and p53 mRNA in stage 1 ESC transfected with empty vector
(Control), or vector encoding w.t. Pax3. Each mRNA was normalized to rRNA. ***p,0.0001 vs. control cells. (F) Immunoblot of Pax3 or p53 in stage 1
ESC stably transfected with empty pCMV vector or pCMV-Pax3. (G) Immunoblot of Pax3 or p53 in stage 1 or stage 3 ESC. Stage 3 ESC were
untransfected, or transfected with empty shRNA vector (pSingle), pSingle expressing a scrambled shRNA sequence (scrambled), and 3 different Pax3
shRNA sequences. Stage 3 cultures were treated or not with doxycycline during days 4–6.
doi:10.1371/journal.pone.0029379.g001
Pax3 Stimulates p53 Ubiquitination
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29379p53 protein (Figure 1 G). These results demonstrate that Pax3, and
not the process of differentiation per se, is responsible for the
decrease in p53 in stage 3 ESC.
Pax3 stimulates p53 ubiquitination and degradation
Treatment of lung carcinoma cells transfected with a PAX3
expression plasmid with cycloheximide suggested that Pax3
stimulates p53 degradation [31], however, whether synthesis of
p53 or synthesis of a regulator of p53 turnover was also inhibited
by cyclohexamide was not determined. To examine whether the
decrease in p53 protein in ESC-derived neuronal precursors was
due to a reduction in protein synthesis, stability, or both, newly
synthesized p53 was pulse labeled with
35S-met. The rate of
incorporation of
35S-met into p53 demonstrated that p53 protein
synthesis was not reduced in stage 3 ESC (Figure 2 A). However,
assay of
35S-met-labeled p53 followed by a chase with unlabeled
met demonstrated that the t1/2 of p53 is reduced approximately 3-
fold in stage 3 ESC compared to stage 1 ESC (Figure 2 B). p53
degradation is stimulated by association with Mdm2 and
activation of Mdm2 ubiquitin ligase activity [32]. To test whether
decreased stability of p53 in stage 3 ESC might be due to increased
ubiquitination, ubiquitinated p53 relative to total p53 was assayed
by immunoblot. The amount of p53 that was ubiquitinated was
significantly increased in stage 3 ESC (Figure 2 C), suggesting that
Pax3 stimulates p53 degradation by promoting its ubiquitination.
Although it is possible that Pax3 could regulate expression of
genes whose products participate in p53 ubiquitination, we
considered that a more rapid modulation of p53 degradation
could be effected if Pax3 physically associates in a complex
containing p53 and Mdm2. To study this, we immunoprecipitated
p53, Pax3, or Mdm2 and examined protein associations by
immunoblot. As shown in Figure 2 D, Pax3 and p53 associated
with each other, particularly using extracts from stage 3 ESC, and
Pax3 also associated with Mdm2. As expected, Mdm2 co-
immunoprecipitated with p53, although more of p53 and Mdm2
were associated with each other using extracts from stage 3 ESC
than from stage 1 ESC. Inasmuch as p53 is less abundant in stage
3 than in stage 1 ESC, it is possible that Pax3 promotes association
of p53 with Mdm2.
We next investigated which structural domains of Pax3 are
responsible for association with p53 or Mdm2. As diagrammed in
Figure 2 E, the structural domains of Pax3 that have been
previously identified include an N-terminal transcription inhibito-
ry domain (ID), the paired domain (PD), a conserved octapeptide
(OCT), the paired-type homeodomain (HD), and a C-terminal
trans-activation domain (TAD). The PD and HD are each
independent DNA-binding domains [3,9,10] that bind to DNA
with higher affinity together than when only one of the domains is
bound together [8], the OCT is necessary for homodimerization
[11], and the ID and TAD possess transcription inhibition and
transcription activation activities, respectively [33]. We construct-
ed plasmids to express glutathione-S-transferase- (GST) and
FLAG-tagged proteins fused with full-length w.t. Pax3, or
fragments containing various Pax3 structural domains. Addition-
ally, we constructed plasmids to express GST or FLAG fused with
the least defective of the proteins encoded by the mutant Pax3
allele, Splotch. The Splotch mutation disrupts the splice acceptor site
of exon 4, resulting in four aberrantly spliced transcripts
[11,34,35]. Three of the predicted protein products cause frame-
shifts beginning in the PD, but the least defective deletes 45 amino
acids that include part of the PD and the OCT (Figure 2 E).
GST fusion proteins were incubated with extracts from stage 1
ESC to determine which Pax3 structures can associate with p53 or
Mdm2 in vitro (Figure 2 F), and plasmids encoding FLAG fusion
proteins were transiently transfected into stage 1 ESC to determine
which Pax3 structures can associate with p53 or Mdm2 in intact
cells in vivo (Figure 2 G). All fusion proteins containing either the
PD or HD associated with p53 and Mdm2 both in vivo and in vitro.
Notably, the PD and HD were each able to associate with p53 and
Mdm2 in the absence of the other DNA-binding domain. p53
associated with Splotch Pax3 at levels comparable to that of w.t.
Pax3 in vitro, but only weakly in vivo. The weak association of Splotch
Pax3 in vivo, despite the presence of the HD, which can associate
with p53 in the absence of other Pax3 structural domains, suggests
that the part of the PD and OCT that are deleted in Splotch Pax3
are necessary to prevent interference by the N-terminal transcrip-
tion inhibitory domain or the C-terminal trans-activation domain
for association of the HD with p53. Mdm2 only weakly associated
with Splotch Pax3 both in vitro and in vivo.
The Pax3 paired domain and homeodomain stimulate
Mdm2-mediated ubiquitination of p53 and p53
degradation
The physical association of Pax3 with p53 and Mdm2 suggested
that Pax3 might regulate p53 ubiquitination. To test this,
ubiquitination of GST-p53 by GST-Mdm2 in the presence or
absence of GST-Pax3 was assayed in vitro. Ubiquitination of GST-
p53 was stimulated by GST-Pax3 in a dose-dependent fashion
(Figure 3 A). This activity was dependent on Pax3 structures, as
GST alone did not stimulate p53 ubiquitination (Figure 3 B).
GST-Pax3 did not stimulate p53 ubiquitination in the absence of
GST-Mdm2 (Figure 3 C), demonstrating that Pax3 was not itself
an ubiquitin ligase, but that it stimulated ubiquitin ligase activity of
Mdm2.
To determine which structural domain(s) of Pax3 are respon-
sible for stimulation of p53 ubiquitination, in vitro ubiquitination of
GST-p53 by GST-Mdm2 with the addition of each of the GST
fusion proteins containing Pax3 structural domains was examined.
Each of the structural domains that are capable of complex
formation with p53 and Mdm2 stimulated ubiquitination of GST-
p53, although the PD appeared to be more potent than the HD
(Figure 3 D). Notably, GST-Splotch Pax3 did not increase
ubiquitination of GST-p53.
To test whether the same Pax3 structural domains that can
stimulate Mdm2-mediated p53 ubiquitination in vitro can stimulate
p53 ubiquitination and degradation upon expression in ESC,
plasmids encoding FLAG fusion proteins were transiently
transfected into stage 1 ESC. As shown in Figure 4 A, the Pax3
structures that contain the PD or the HD, except for Splotch Pax3,
stimulated p53 ubiquitination in vivo, just as they did in vitro.
Transfecting increasing concentrations of plasmids encoding
FLAG fusion proteins caused a dose-dependent decrease in steady
state levels of p53 only if they encoded Pax3 structures that were
capable of stimulating p53 ubiquitination (Figure 4 B, C). Because
each of the PD and HD were capable of stimulating p53
ubiquitination and down regulation when they were expressed in
the absence of the C-terminal trans-activation domain or the N-
terminal transcription inhibitory domain, this indicates that down
regulation of p53 does not require Pax3 to function as a
transcriptional regulator. There was no effect of increasing
concentrations of FLAG-Splotch Pax3 on p53 steady state levels.
This is not due to decreased stability of the Splotch Pax3 protein,
because steady-state levels of FLAG-Splotch Pax3 were similar to
those of FLAG-w.t. Pax3 (Figure 4 B, C). Instead, the failure of
Splotch Pax3 to decrease p53 levels appears to be due to defective
association of Splotch Pax3 with p53 and Mdm2, and failure to
stimulate Mdm2 ubiquitin ligase activity.
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35S-met to determine the rate of p53 synthesis in stage1 and stage 3 ESC. Quantitation of
35S-p53 is described in the supporting online material. (B)
Pulse-chase labeling to determine the t12 of p53 in stage 1 and stage 3 ESC. (C) Quantitation of ubiquitinated p53/total p53 in stage 1 and stage 3 ESC
following immunoprecipitation of p53 and immunoblotting using anti-ubiquitin or anti-p53 antibodies. *p,0.05 vs. stage 1. (D) Whole cell extracts of
stage 1 or stage 3 ESC were immunoprecipitated using antibodies against p53, Pax3 or Mdm2, and then immunoblotted using antibodies against
p53, Pax3, and Mdm2. (E) Schematic diagram of full-length w.t. Pax3, Pax3 structural domains, and a Splotch Pax3 (Sp) protein product that were
expressed as GST and FLAG fusion proteins. N-term, amino-terminus of Pax3 through the homeodomain; C-term, carboxy-terminus distal to the
homeodomain (including the trans activation domain); DBD, DNA-binding domain (PD through HD); ID, the trans-activation inhibitory domain
(amino-terminal to the PD); PD, paired domain; OCT, octapeptide (carboxy-terminal of the PD to amino-terminal of the HD); and HD, homeodomain.
The Splotch cDNA deletes exon 4 and lacks coding sequence for part of the PD and the OCT but retains the HD. Numbers refer to amino acid
positions of w.t. Pax3. (F) Immunoblot using antibodies against p53 (upper panel), Mdm2 (middle panel), or GST following incubation of whole cell
lysates from stage 1 ESC with GST-Pax3 fusion proteins linked to glutathione-sepharose beads. (G) Immunoblot using antibodies against p53 (upper
panel), Mdm2 (middle panel), or FLAG following incubation of whole cell lysates from stage 1 ESC that had been transiently transfected with plasmids
encoding FLAG-tagged Pax3 fusion proteins with antibody against FLAG linked to M2 beads.
doi:10.1371/journal.pone.0029379.g002
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It has long been recognized that Pax3 is essential for formation of
the neural tube and neural crest-dependent structures. Until now, it
has been believed that the activity of Pax3 as a DNA-binding
transcription factor is responsible for these functions, and that the
phenotype of Pax3
Sp/Sp embryos is due to loss of transcription factor
activity of Splotch Pax3 [11,35]. Our previous studies demonstrated
that neural tube closure, cardiac neural crest migration, and cardiac
outflow tract septation proceeds normally in Pax3
Sp/Sp and Pax3-null
embryos as long as p53 is inactivated [25,27], demonstrating that
Pax3 is required for these processes only to inactivate p53. The
results presented here demonstrate that Pax3 inactivates p53 by
stimulating its degradation and that stimulation of p53 degradation
occurs independent of Pax3 binding to DNA and regulation of
transcription. Therefore,while Pax3 may, in addition, regulate gene
expression during neural tube and neural crest development, our
results indicate that Pax3 is required in order to effect neural tube
closure and neural crest-dependent cardiac outflow tract septation
only to stimulate p53 ubiquitination and degradation independent
of transcription. Moreover, these findings show that the mutant
SplotchPax3 allele isdefectiveinassociatingwithp53and Mdm2and
fails to stimulate p53 ubiquitination and down regulation. Because
stimulation of p53 degradation by w.t. Pax3 occurs independent of
its activity as a transcription factor, this indicates that Splotch Pax3 is
functionally null, not because it is defective as a transcription factor,
but because it fails to effectively complex with p53 and Mdm2 and
to stimulate Mdm2-mediated ubiquitination of p53.
Associations of the Pax3 PD and HD with other proteins,
including the retinoblastoma tumor suppressor protein (Rb),
Msx1, Mox1 and Mox2, and Ets have been reported
[36,37,38,39]. However, each of these associations functioned to
block Pax3 binding to DNA and activating transcription. In
contrast, the association of the Pax3 DNA-binding domains with
p53 and Mdm2 that are reported here confers an activity on these
domains separate from gene regulation.
Additionally, our findings suggest that human diseases associ-
ated with PAX3 may be explained by insufficient or excessive p53
degradation. For example, almost all of the 76 different PAX3
mutations that have been identified in WS type 1 and type 3 are
localized to the PD, the OCT, or the HD (Figure S1 and Table
S6). Because these mutations interfere with the transcription factor
activity of PAX3, it has been widely accepted that altered
expression of PAX3 target genes is responsible for the WS
phenotype. However, our results predict that mutation of these
PAX3 domains ought to also impair stimulation of HDM2-
mediated ubiquitination of p53. Thus, failure to block p53-
dependent processes, rather than altered expression of PAX3
target genes, may be responsible for the WS phenotype. It is
intriguing to speculate that WS PAX3 proteins compete with w.t.
PAX3 for associating with p53 or HDM2 and behave as trans-
dominant mutants. This could explain why the WS PAX3 alleles,
which appear to be loss-of-function mutations, cause an autosomal
dominant disease. Further research will be necessary in order to
determine whether this is the case. On the flip side, PAX3 over
expression occurs in many neural crest or neuroectodermal tumors
Figure 3. Pax3 stimulates Mdm2-mediated ubiquitination of p53 in vitro. (A) In vitro ubiquitination reactions of GST-p53 with GST-Mdm2
(150 ng), and 0–1600 ng GST-Pax3. Ubiquitination was assayed by immunoblot using 53 antibodies. The position of GST-p53 is indicated by a heavy
arrow, and the positions of ubiquitinated p53 are indicated by narrow arrows. (B) In vitro ubiquitination reactions as in (A) except that GST without
any Pax3 coding sequences was used. (C) In vitro ubiquitination reactions performed with only GST-Mdm2 or 400 ng GST-Pax3. (D) In vitro
ubiquitination reactions of GST-p53 with GST-Mdm2 and 400 ng GST fusion proteins of w.t. Pax3, Pax3 structural domains, or Splotch Pax3. (The GST-
p53 and GST-Mdm2 vectors used here encoded murine p53 and Mdm2, although similar results were obtained using human p53 and Mdm2 fusion
proteins (data not shown).)
doi:10.1371/journal.pone.0029379.g003
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[40,41,42,43,44]. The p53 gene is rarely deleted or mutated in
these tumors [45,46]. Thus, p53 loss of function may be
accomplished by physical interaction with PAX3, and this may
be crucial to the oncogenesis of these tumors. Other Pax proteins
have oncogenic potential, as indicated by fibroblast transformation
[47]. However, only Pax5 has been shown to regulate p53, and
this was by direct transcription inhibition [48]. Whether down
regulation of p53 by either transcriptional or post-transcriptional
mechanisms is a general property of the Pax family remains to be
determined.
Our conclusions may appear audacious given the existing
dogma that Pax3 regulates neural tube closure and cardiac neural
crest development by virtue of its activity as a transcription factor.
However, reexamination of the existing literature in light of our
findings can reveal a new paradigm of the mechanism by which
Pax3 regulates neural tube and neural crest development. In
particular, there are several genes, including two identified by us,
whose expression is increased or decreased by Pax3
[12,13,14,15,16,17,18,19,20,21,22,23]. Nonetheless, heretofore
there is little functional evidence that Pax3 directly regulates any
of these putative target genes and that they are mechanistically
involved in neural tube closure or neural crest development. The
only gene for which there is functional evidence is Msx2, whose
expression is negatively regulated by Pax3 in the neural tube and
neural crest [19]. Msx2 loss-of-function (Msx2
2/2) rescued COTD
and embryonic lethality in Pax3
Sp/Sp embryos, although NTD were
not rescued [19]. This evidence notwithstanding, the putative
Pax3 binding site within the Msx2 promoter is low affinity [8],
suggesting that Pax3 might not directly regulate Msx2 under
physiological conditions. There is evidence that Msx2 expression is
upregulated along with p53 [49], suggesting that Msx2 might be a
direct or indirect target of p53. Thus, while Pax3 can directly
regulate Msx2 under experimental conditions, effects of Pax3 on
Msx2 expression in embryonic cardiac neural crest may be indirect
and mediated by altered p53 levels. The failure of Msx2 deletion to
rescue NTD in Pax3
Sp/Sp embryos indicates that Msx2 is not a
functional target of Pax3 in the neural tube, or that its
downregulation is not sufficient to mediate effects of Pax3 on
neural tube closure.
Interestingly, it was recently reported, using conditional deletion
of Pax3 in premigratory and/or migratory neural crest, that Pax3
is only required for expression in early premigratory and
migratory cardiac neural crest [50]. This is consistent with our
findings, using pifithrin-a, that inhibition of p53 by Pax3 is only
required during approximately the first 4 hours after the onset of
Figure 4. The Pax3 domains that associate with p53 and Mdm2 stimulate p53 ubiquitination and down regulation in vivo. (A)
Quantitation of in vivo ubiquitination of p53 in stage 1 ESC that were untransfected, or transiently transfected with 4 mg FLAG-tagged vectors
encoding w.t. Pax3, Pax3 structural domains, or Splotch Pax3. *p,0.05, **p,0.01. (B) Immunoblot analyses of whole cell extracts from Stage 1 ESC
that were untransfected, or transiently transfected with 1–4 mg FLAG-tagged vectors as in (A) using antibodies against FLAG, p53, or b-actin. (C)
Quantitation of FLAG or p53 relative to b-actin from three replicate transfected culture dishes assayed as in (B).
doi:10.1371/journal.pone.0029379.g004
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migration and outflow tract septation to occur [25]. Thus, while
Pax3-linked reporter gene expression can be detected in cardiac
neural crest cells at least through the 35 somite stage (approxi-
mately E9.5) [25], it is only required to block p53-dependent
processes that are required for subsequent outflow tract septation
in early premigratory and migratory cardiac neural crest cells.
Our findings lead to the overarching question of why it is
necessary for Pax3 to functionally inactivate p53 during embryonic
development. Studies using ESC or generation of induced
pluripotent stem (iPS) cells have indicated that p53 is activated
during ESC differentiation, and that activation of p53 inhibits self-
renewal and promotes differentiation [51,52,53,54,55]. Thus, it
may be necessary for Pax3 to titrate the activity of p53 once
embryonic cells start to differentiate along a neural lineage in
order to prevent premature loss of proliferative capability and
multipotency until a critical cell mass or cellular localization is
achieved.
Materials and Methods
Ethics Statement
Mouse embryos used for recovery of RNA for generation of p53
and Mdm2 expression plasmids were obtained from pregnant
mice on E10.5 using procedures that are approved by the Joslin
Diabetes Center Institutional Animal Care and Use Committee
under Protocol #92-06.
Embryonic Stem Cell Culture
Mouse D3 ESC (ATCC) were cultured and induced to form
neuronal precursors as described [29], except that 0.5 mM retinoic
acid (Sigma) was added to embryoid body cultures. Briefly, cells
were grown as undifferentiated, monolayer cultures (referred to as
stage 1) on 0.1% gelatin-coated tissue culture dishes (without
mouse embryo fibroblasts) in DMEM (Invitrogen) containing 10%
fetal calf serum (Atlanta Biologicals), 110 mM b-mercaptoethanol
(Sigma), 1000 units/ml of leukocyte inhibitory factor (LIF), 2 mM
glutamine, 16nucleosides, 16nonessential amino acids (all from
Millipore), and 16penicillin/streptomycin (Invitrogen). To induce
differentiation to neuronal precursors, stage 1 cultures were
trypsinized, and were induced to form embryoid bodies (referred
to as stage 2) in bacterial grade culture dishes containing stage 1
media with 0.5 mM retinoic acid, but without LIF, for 4 days, then
were transferred to tissue culture dishes in DMEM:F12 media
(Invitrogen) containing fibronectin (Becton Dickenson), insulin,
transferrin, and selenium (Sigma) for up to 4 days (referred to as
stage 3). All experiments were performed using cells that had
undergone fewer than 40 passages.
Plasmid Constructions
Short hairpin RNA (shRNA) sequences targeting Pax3 mRNA
were designed using the shRNA Sequence Designer (Clontech), and
a scrambled sequence was designed using BLOCK-iT RNAi
Designer (Invitrogen). Three Pax3-targeted shRNA sequences and
the scrambled sequence (Table S1) were inserted into the Xho1 and
HindIII sites of pSingle-tTS-shRNA (Clontech). Presence of inserts
was determined by restriction digestion with MluI (Promega).
GST fusion plasmids encoding w.t. Pax3, the amino-terminus,
carboxy-terminus, DBD, ID, PD, OCT, and HD (see Figure 2 E)
were generated as described [8], except using primers and PCR
conditions shown in Table S2. The Splotch Pax3 cDNA was
generated by PCR of GST-w.t. Pax3 to delete exon 4 (nt 839–973)
which encodes the C-terminal 14 amino acids of the PD and the
OCT; this cDNA encodes the only in-frame Pax-3 mRNA
produced in Sp/Sp mutants [34,35]. GST fusion proteins encoding
murine Mdm2 and p53 coding were generated using cDNA
obtained from E 10.5 mouse embryos.
FLAG fusion vectors were constructed by removing the Pax3
coding sequences from the GST fusion plasmids with BamHI and
EcoRI and inserting them into the BamHI and EcoRI sites of
pCMV-Tag2C (Stratagene). The plasmids were grown in DH5a
competent E. coli (Invitrogen) and purified using Qiagen plasmid
preparation kits (Qiagen, Inc.).
All PCR were performed using Taq ready mix (Sigma, St Louis,
MO), except the PCR to generate the Splotch Pax3 internal
deletion, in which PfuUltr High Fidelity DNA polymerase
(Stratagene, La Jolla, CA) was used. The PCR products were
inserted into pGEX-3X (GE healthcare, Piscataway, NJ) that had
been digested with BamHI and EcoRI (New England Biolabs Inc.,
Ipswich, MA). To construct GST-Splotch Pax3, a linear PCR
product was generated using GST-Pax3 FL as template, and
primers that would amplify all of the plasmid except nt 839–973
(exon 4). The methylated template was digested with DpnI (New
England Biolabs Inc., Ipswich, MA). To generate GST fusion
proteins encoding murine Mdm2 and p53, total RNA from whole
mouse embryos was reverse transcribed as described [56], and the
resulting cDNA was amplified using primer sequences, above. The
p53 PCR product was digested with BamHI and EcoRI and
inserted into the BamHI and EcoRI sites of pGEX-3X. The
Mdm2 PCR product was digested with BglII and EcoRI and
inserted into the BamHI and EcoRI sites of pGEX-3X. All
plasmids were grown using competent Rosetta cells (Novagen,
Madison, WI). DNA sequencing by the Dana-Farber/Harvard
Cancer Center DNA Resource Core confirmed the accuracy of
cDNA sequences within all recombinant plasmids.
Transfection of ESC
All transient and stable transfections of stage 1 ESC were
performed using Lipofectamine 2000 (Invitrogen) at a concentra-
tion of 10 mg/ml. Stable transfectants were selected using 400 mg/
ml of G418 (Invitrogen). Transient transfection cultures were
terminated 48 h after transfection.
pCMV-Pax3 [8,47] or empty CMV vector [8] were stably
transfected into cells in 35 mm dishes using 1.8 mg plasmid DNA.
Recombinant shRNA plasmids targeting Pax3 mRNA, or empty
vector were stably transfected into cells in 35 mm dishes using
2 mg plasmid DNA. To induce shRNA expression, ESC were first
differentiated to stage 3, then 1 mg/ml of doxycycline (Clontech)
was added to media on day 4 of stage 3 ESC cultures. Cultures
were harvested 48 h after doxycycline administration.
Association of FLAG-Pax3andPax3domainfusion proteinswith
endogenous ESCproteinswasstudied usingtransienttransfectionof
ESC grown in 10 cm plates with 24 mg plasmid DNA. The effect of
increasing expression of FLAG-Pax3 and Pax3 domain fusion
proteins on p53 protein was tested using transient transfection of
ESC in 35 mm plates with 0, 1, 2, or 4 mg plasmid DNA.
Real time RT-PCR
Total RNA was extracted using Ultraspec (Biotecx Laborato-
ries). Real-time RT-PCR was performed in quadruplicate as
described using rRNA as the normalization control [57]. Primer
and probe sequences for Pax3 and p53 were as previously reported
[57,58]. Primers and probes for rRNA and Nestin were obtained
from PerkinElmer.
Immunoblot Analyses
Whole cell extracts were prepared and analyzed by immunoblot
as described [27,59]. Antibodies and their working dilutions of
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Antibodies coupled to horseradish peroxidase (HRP) were
detected by chemiluminescence (PerkinElmer) and exposure to
x-ray film. Band intensity was quantified using Adobe Photoshop
(Version 9.01).
Immunoprecipitation
Two hundred mg protein from whole cell extracts were pre-
cleared at 4uC for 1 hour with 10 mg non-immune IgG and 10 ml
of 50% protein A/G beads (Santa Cruz Biotechnology). The pre-
cleared extract was incubated with appropriate antibodies (Table
S4) while rocking at 4uC overnight. Protein A/G beads were
added for one hour prior to precipitation. The precipitated
proteins were analyzed by immunoblot as above.
Immunofluorescence microscopy
ESC were grown on gelatin-coated cover slips. Cells were fixed
with 4% paraformaldehyde, permeabilized with 10% Triton X-
100-PBS, blocked in 5% BSA-PBS, and washed in 1% BSA-PBS.
The cells were then incubated with primary antibodies at 4uC
overnight, and secondary antibodies for 1 hour in the dark at
room temperature (see Supplementary Table S5 for antibody
details). Cells were counterstained for 5 min. with 300 nM DAPI
in PBS. Both antibody incubations were followed by three
10 minutes washes in PBS. Cells were imaged with a Nikon 80i
fluorescence microscope.
Measurement of rates of p53 protein synthesis and decay
p53 synthesis in stage 1 and stage 3 ESC was assayed by pulse
labeling with
35S-methionine. Briefly, cultures were incubated in
cysteine- and methionine-free DMEM for 15 minutes. The media
were replaced with cysteine- and methionine-free media contain-
ing 0.17 mCi/ml
35S-methionine (1175 Ci/mmol) and cultures
were incubated for times indicated. p53 was immunoprecipitated
from whole cell extracts, electrophoresed, and immunoblotted.
p53 bands were cut from nitrocellulose filters and were counted in
a scintillation counter (Beckman Coulter). The relative amount of
newly synthesized p53 was expressed as
35S-cpm/p53 immuno-
reactivity (determined by scanning and quantitation of x-ray film).
Curves were compared using nonlinear regression.
The rates of p53 decay in stage 1 and stage 3 ESC were assayed
by pulse-chase labeling. Briefly, cells were labeled with
35S-
methionine-containing media as above for 1 hour. Media were
removed, cultures were rinsed two times with PBS, and were then
incubated in complete DMEM. The amount of
35S-p53 at each
time point was quantitated as above. Nonlinear regression was
used to calculate the half-life of p53.
In vitro GST Fusion Protein Association Assay
Expression of GST fusion proteins by Rosetta E. coli was
induced as described [60]. GST fusion proteins were isolated as
described [8]. Five hundred mg protein from stage 1 whole cell
lysates were incubated with glutathione-sepharose beads (GE
healthcare, Piscataway, NJ) coupled to GST fusion proteins,
according to the manufacturer’s instructions. The ESC proteins
that co-precipitated with GST fusion proteins were identified by
immunoblot using antibodies listed in Table S3.
In vivo FLAG Fusion Protein Association Assay
Whole cell lysates were prepared from ESC transiently
transfected with FLAG fusion proteins. 500 mg protein were
immunoprecipitated with anti-FLAG M2 agarose (Table S4)
according to the manufacturer’s instructions. The ESC proteins
that co-precipitated with FLAG fusion proteins were identified by
immunoblot using antibodies listed in Table S3.
In vitro Ubiquitination Assay
In vitro ubiquitination reactions were performed as described
[60]. The reaction mixture (20 ml) contained 10 ng GST-p53
(murine), 24 ng E1 (Boston Biochem), 20 ng GST-UbcH5C
(Boston Biochem), 150 ng GST-Mdm2 (murine), 10 mg His-
ubiquitin (Boston Biochem), plus GST fusion proteins containing
full length Pax3 or Pax3 domains. After incubation at 37uC for
60 min, the reaction products were terminated with stop buffer
(Boston Biochem). Ubiquitinated and unubiquitinated p53 were
detected by immunoblot using goat anti-p53 antibodies.
In vivo Ubiquitination Assay
Whole cell lysates were prepared from stage 1 or stage 3 ESC,
or from stage 1 ESC transiently transfected for 48 h with 4 mg
FLAG-tagged plasmid DNA in 35 mm plates. 500 mg protein were
pre-cleared and immunoprecipitated with anti-p53 antibodies
(Ab1 and Ab3) and protein A/G beads at 4uC overnight. The
precipitated proteins were analyzed by immunoblot with anti-
ubiquitin antibodies.
Statistical Analyses
All statistical analyses were performed using GraphPad Prism
software v. 4.0. Data shown are mean 6 S.E.M.
Supporting Information
Figure S1 Locations of Waardenburg syndrome types 1
and 3 mutations within PAX3. The major structural domains
and locations of intron-exon borders are shown. Mutations
causing premature termination are shown above the protein
structure, and those that do not cause premature termination
(frame-shift or deletion) are shown below the protein structure.
Mutations associated with WS3 are shown in italics. Mutations
caused by nucleotide insertions or deletions are indicated by nt
location and number of inserted or deleted nt; mutations caused
by point mutations are indicated by amino acid substitutions.
Further description of PAX3 mutations associated with WS1 and 3
and references are located in Table S6.
1Patient with WS3 is
homozygous for mutation; *2 unrelated families share identical
mutations;
#3 unrelated families share identical mutations;
abase
substitution at nt +1 within intron 3 abolishes splice donor
sequence, causing translation of intron 3 and termination within
the PD;
bbase substitution at the splice acceptor site of intron 3
causes deletion of exon 4;
cbase substitution in the splice donor site
of intron 5 causes termination after exon 5. Pax3 structural
domains are labeled as in Figure 2.
(TIF)
Table S1 Oligonucleotide Sequences for Pax3 shRNA.
Short hairpin RNA (shRNA) sequences targeting Pax3 mRNA
were designed and inserted into pSingle-tTS-shRNA (Clontech) as
described in Supplementary Materials and Methods. Xho I sites
are highlighted in green; short hairpin sequences are highlighted in
yellow; Mlu I sites are highlighted in purple; Hind III sites are
highlighted in turquoise.
(DOC)
Table S2 Primer sequences and PCR conditions for
construction of GST fusion proteins. Key: FL, full length;
DBD, DNA-binding domains; ID, inhibitory domain; PD, paired
domain; OCT, conserved octapeptide; HD, homeodomain.
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‘‘+1’’ corresponding to the transcription initiation site.
(DOC)
Table S3 Immunoblot Antibodies. Antibodies used for
immunoblot, their dilutions, species of origin, and commercial
sources.
(DOC)
Table S4 Immunoprecipitation Antibodies. Antibodies
used for immunoprecipitation, amounts used, species of origin,
and commercial sources.
(DOC)
Table S5 Immunofluorescence Antibodies. Antibodies
used for immunoprecipitation, dilutions, species of origin, and
commercial sources.
(DOC)
Table S6 Waardenburg Syndrome Types 1 and 3
Mutations. Summary of currently identified PAX3 mutations
associated with Waardenburg Syndromes Types 1 and 3 and
effects on PAX3 protein.
(DOC)
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